Duchi S, Dambruoso P, Martella E, Sotgiu G, Guerrini A, Lucarelli E, Pessina A, Coccè V, Bonomi A, Varchi G
Osteoarticular Regeneration Laboratory, Rizzoli Orthopaedic Institute , 40136 Bologna, Italy.
Bioconjug Chem. 2014 Apr 16;25(4):649-55. doi: 10.1021/bc5000498. Epub 2014 Mar 19.
Human mesenchymal stem cells (hMSC) are multipotent cells that display the unique ability to home and engraft in tumor stroma. This remarkable tumor tropic property has generated a great deal of interest in many clinical settings. Recently, we showed that hMSC represent an excellent base for cell-mediated anticancer therapy since they are able to internalize paclitaxel (PTX) and to release it in an amount sufficient to inhibit tumor cell proliferation. In order to shed light on the dynamics of drug uptake and release, in the present paper we describe the synthesis of two novel thiophene-based fluorophore-paclitaxel conjugates, namely PTX-F32 and PTX-F35, as tools for in vitro drug tracking. We aimed to study the ability of these novel derivatives to be efficiently internalized by hMSC and, in a properly engineered coculture assay, to be released in the medium and taken up by tumor cells. In order to ensure better stability of the conjugates toward enzymatic hydrolysis, the selected oligothiophenes were connected to the taxol core at the C7 position through a carbamate linkage between PTX and the diamino linker. Antiproliferative experiments on both tumor cells and stromal cells clearly indicate that, in good correlation with the parent compound, cells are sensitive to nanomolar concentrations of the fluorescent conjugates. Moreover, in the coculture assay we were able to monitor, by fluorescence microscopy, PTX-F32 trafficking from hMSC toward glioblastoma U87 tumor cells. Our work paves the way for novel possibilities to perform extensive and high quality fluorescence-based analysis in order to better understand the cellular mechanisms involved in drug trafficking, such as microvescicle/exosome mediated release, in hMSC vehicle cells.
人骨髓间充质干细胞(hMSC)是多能细胞,具有归巢并植入肿瘤基质的独特能力。这种显著的肿瘤趋向性特性在许多临床环境中引起了极大的兴趣。最近,我们发现hMSC是细胞介导的抗癌治疗的理想基础,因为它们能够内化紫杉醇(PTX)并以足以抑制肿瘤细胞增殖的量释放它。为了阐明药物摄取和释放的动力学,在本文中我们描述了两种新型基于噻吩的荧光团 - 紫杉醇缀合物(即PTX - F32和PTX - F35)的合成,作为体外药物追踪的工具。我们旨在研究这些新型衍生物被hMSC有效内化的能力,并在适当设计的共培养试验中,使其释放到培养基中并被肿瘤细胞摄取。为了确保缀合物对酶促水解具有更好的稳定性,所选的寡噻吩通过PTX与二氨基连接体之间的氨基甲酸酯键在C7位置连接到紫杉醇核心。对肿瘤细胞和基质细胞的抗增殖实验清楚地表明,与母体化合物密切相关,细胞对纳摩尔浓度的荧光缀合物敏感。此外,在共培养试验中,我们能够通过荧光显微镜监测PTX - F32从hMSC向胶质母细胞瘤U87肿瘤细胞的转运。我们的工作为进行广泛且高质量的基于荧光的分析开辟了新的可能性,以便更好地理解hMSC载体细胞中药物转运所涉及的细胞机制,如微泡/外泌体介导的释放。